Cantabio Pharmaceuticals Inc. announced a new preclinical therapeutic program for Alzheimer's Disease which it is pursuing through its drug discovery partnership with NovAliX. This program is aimed at the development of small molecule chaperones that stabilize the Abeta peptide, the aggregation of which is considered to be a key element in the onset and progression of Alzheimer's disease. This new program, which is the result of collaborative work between Cantabio and NovAliX, is based on the discovery of novel small molecules that interact with the Abeta peptide, which were identified using NovAliX's high throughput chemical microarray based surface plasmon resonance (SPR-WORM) screen, a unique high throughput biophysics based binding assay platform.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.01 USD | -95.96% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 24.35K | |
+1.85% | 42.75B | |
+47.70% | 41.61B | |
+12.43% | 41.34B | |
-8.83% | 26.59B | |
+7.52% | 25.49B | |
-23.07% | 18.12B | |
+30.55% | 12.24B | |
-2.03% | 11.76B | |
+8.19% | 11B |
- Stock Market
- Equities
- CTBO Stock
- News Cantabio Pharmaceuticals, Inc.
- Cantabio Pharmaceuticals Inc. Announces the Development of Small Molecule Chaperones of the Abeta Peptide for the Treatment of Alzheimer's Disease in Collaboration with Novalix